PEPTIDE COMPARISON

Retatrutide vs Semaglutide

Investigational triple-receptor research compared with a mature GLP-1 evidence base.

QUICK ANSWER

Retatrutide vs Semaglutide: the main difference.

Retatrutide may ultimately differ in effect because of its triple-receptor design, but semaglutide currently has the much deeper approved-use and outcomes evidence base.

Decision field	Retatrutide	Semaglutide
Human research	Published Phase 2; Phase 3 development	Multiple large Phase 3 and outcomes programs
Receptors	GIP + GLP-1 + glucagon	GLP-1
FDA status	Investigational; not approved	Approved products for defined indications
Availability	Clinical research only	Prescription medicine under labeled use
Evidence confidence	Promising but incomplete	High for labeled indications

SOURCES

Retatrutide vs Semaglutide sources.

Human trial / 2023Triple-hormone-receptor agonist retatrutide for obesity — Phase 2New England Journal of Medicine / PubMed Registry / 2023Retatrutide Phase 2 obesity studyClinicalTrials.gov FDA / 2026FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. FDA FDA / 2026Wegovy application and labeling recordU.S. FDA

Retatrutide vs Semaglutide: the main difference.

Retatrutide vs Semaglutide sources.

Questions related to Retatrutide vs Semaglutide.

Compare the next decision.